Post-COVID Clinical Research Resilience in China
Post-COVID Clinical Research Resilience in China Building Resilience in China’s Clinical Research After COVID-19 Introduction The COVID-19 pandemic disrupted clinical research worldwide, and China—one of the earliest epicenters—faced unprecedented challenges in sustaining ongoing trials while initiating new ones. Site closures, supply chain disruptions, and patient safety concerns forced sponsors, CROs, and regulators to adapt rapidly….
Read More “Post-COVID Clinical Research Resilience in China” »